Johnson & Johnson Reports 2017 Third-Quarter Results:
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Johnson & Johnson (JNJ) PT Raised to $145 at Morgan Stanley
October 18, 2017 7:49 AM EDTMorgan Stanley raised its price target on Johnson & Johnson (NYSE: JNJ) to $145.00 (from $140.00) while maintaining a Overweight rating.
... MoreJohnson & Johnson (JNJ) PT Raised to $161 at Jefferies
October 18, 2017 7:30 AM EDTJefferies raised its price target on Johnson & Johnson (NYSE: JNJ) to $161.00 (from $160.00) while maintaining a Buy rating following beat and raise results.
Analyst Jeffrey Holford notes their revenue and adjusted EPS estimates remain well above consensus.
"The Pharma division remains under-modeled by... More
Johnson & Johnson (JNJ) PT Raised to $165 at Leerink Partners
October 18, 2017 7:03 AM EDTLeerink Partners raised its price target on Johnson & Johnson (NYSE: JNJ) to $165.00 (from $150.00) while maintaining a Outperform rating.
Analyst Danielle Antalffy said outperformance highlights momentum. 217/2018 outlook moves higher.
... MoreJohnson & Johnson (JNJ) Tops Q3 EPS by 10c; Raises Outlook
October 17, 2017 6:42 AM EDTJohnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.90, $0.10 better than the analyst estimate of $1.80. Revenue for the quarter came in at $19.7 billion versus the consensus estimate of $19.28 billion.
GUIDANCE:
Johnson & Johnson raised its FY outlook. The company sees FY2017 EPS of... More
